APLN and metabolic dysfunction-associated steatohepatitis: In addition, analyses using liver and serum samples from non-NAFLD, NAFLD-NASH, and NASH-Cirrhosis patients revealed that TM4SF5 tended to increase as NAFLD developed along with serum apelin level enhancement, insulin resistance, and cholesterol enrichment.